Navigation Links
New Drug Slows Thyroid Cancer
Date:7/2/2008

Research also uncovers a genetic mutation that improves response to therapy

WEDNESDAY, July 2 (HealthDay News) -- An experimental drug that inhibits tumor blood vessel formation slows the progression of metastatic thyroid cancer in some patients, an international study finds.

Of the 93 patients with rapidly progressing cancer, 49 had a positive response to treatment with motesanib diphosphate. Of those 49 patients, 14 percent had their tumors shrink and 35 had their tumors stabilize for more than 24 weeks. Median progression-free survival was about 40 weeks.

Genetic analysis of 25 patients revealed that drug response was better in those with a mutation known as BRAF V600E in their tumors than in those without the mutation. Further research into this genetic connection is needed, the researchers said.

"Finding that patients whose tumors bear a particular mutation were more likely to respond to the drug is an example of where we would like to head in our research," study author Dr. Steven I. Sherman, chairman and professor of the department of endocrine neoplasia and hormonal disorders at the University of Texas M.D. Anderson Cancer Center, said in a prepared statement.

"This is the first of the various thyroid cancer trials to identify specific mutations that might allow us to individualize or personalize therapy," he said.

The study, published in the July 3 issue of the New England Journal of Medicine, was funded by drug maker Amgen Inc.

Motesanib diphosphate -- a VEGF inhibitor -- targets a protein called vascular endothelial growth factor (VEGF), which plays a critical role in the formation of new blood vessels that allow tumors to grow and spread.

Currently, there are few treatment options for metastatic thyroid cancer.

"There is no standard accepted chemotherapy for advanced metastatic differentiated thyroid cancer, and response rates have typically been
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Anti-Mucus Drug Slows Symptoms of COPD
2. New Compound Slows HIV Replication
3. Treating safety research like other clinical studies slows progress
4. Historic Fundraising Initiative to Empower Women & Girls Worldwide Reaches $100 Million Quickly Even as U.S. Economy Slows
5. Green Tea, Mushroom Extract Combo Slows Sarcomas
6. Diabetes Drug Slows Clogging of Arteries
7. Lithium chloride slows onset of skeletal muscle disorder
8. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
9. High zinc status in lung cells slows growth and induces DNA damage-induced gene expression
10. Viral Therapy Slows Pediatric Tumors in Mice
11. Targeting astrocytes slows disease progression in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... On Thursday, May 14, the Mesothelioma ... Dr. Evan Alley both of the University of ... series. The interview was part of the series ... Drs. Simone and Alley were interviewed by the ... they discussed the mesothelioma program at the University ...
(Date:5/30/2015)... 2015 Responding to surging demand from ... experienced OGAWA products while abroad, OGAWA-engineered massage products have ... A leader in the Asian health and wellness industry ... developer and manufacturer of health and wellness equipment. ... their products, health enthusiasts in Asia and Australia, as ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The iconic ... Jones, will be hosting a new segment on Medical ... aspects of medical malpractice in the health care field. ... 2014 thousands of medical malpractice suits were filed, roughly ... 50% were settled out of court, while the remaining ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... Drought Tolerance, DES MOINES, Iowa, Feb. 4 ... today for a three-day project review,meeting focused on ... DD ) business Pioneer-Hi-Bred, the intent of ... and private organizations in order to,help increase farm ...
... The Beryl Companies announced today the,appointment ... president of,marketing communications. In this role, she ... branding initiatives, working closely,with sales, customer relations ... extensive background in marketing communications,research and operations ...
... by more than 78% , , MONDAY, Feb. 4 (HealthDay News) ... down, a new study shows it may also ease the ... simple sugar-and-water solution will also ease parents, fears and boost ... parents to get their children vaccinated," said study author Linda ...
... - Advocacy Group Urges Russian President Vladimir Putin to Adopt a ... ... The Movement Against Cancer, a cancer,patient advocacy group in Russia, ... inadequate access for cancer,patients in Russia to innovative and effective treatments, ...
... Calif., Feb. 4 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... announced that Jerry McMahon, Ph.D., chairman and CEO,will ... Investor Conference 2008 on,Monday, February 11, at 11:45 ... Dr. McMahon will provide a corporate overview, ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) plans ... a press release before the market opens,on Tuesday, Feb. ... a conference call to review,the financial results, outlook and ... the live conference call via telephone:, Dial in: ...
Cached Medicine News:Health News:DuPont Hosts Meeting of Leading Plant Scientists to Improve World Agricultural Productivity 2Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2
(Date:5/29/2015)... , May 29, 2015 Amgen (NASDAQ: ... two pivotal Phase 3, global, randomized, placebo-controlled trials ... treatment of secondary hyperparathyroidism (SHPT) in patients with ... met the primary endpoint, demonstrating that a greater ... achieved a greater than 30 percent reduction in ...
(Date:5/29/2015)... Pa. , May 29, 2015 ... focus of the Association for the Advancement of ... With support from AAWC,s corporate partners, ... Educational Portal on the AAWC website at ... a wound care pathway with links to various ...
(Date:5/28/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ... with buyers to divest in the United ... assets, Biomet Discovery® Elbow System assets and Cobalt™ bone ... Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... constructively with the Bureau of Competition Staff of the ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Reportlinker.com announces that a new market research ... Triple Analysis: Lung Cancer, Lymphoma ... This triple analysis ... both Lung Cancer and Lymphoma and by ...
... 23, 2011 Applied Medical today announced that it ... Covidien) on May 17, 2011 in the U.S. District ... a recently issued Applied Medical trocar seal patent by ... Action No. CV 11-4203 VBF (AJWx). The patent is ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... Self-Sampling: ,Place the ImmunoDip into ... precise amount of sample needed for,an accurate ... run to completion,in 3 minutes. , ... color bands remain stable,for at least eight ...
Medicine Products: